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Abstract:
Investigation of kinase-related processes often uses pharmacological
inhibition to reveal pathways in which kinases are involved. However, one
concern about using such kinase inhibitors is their potential lack of specificity.
Here, we report that the calcium-calmodulin dependent kinase II (CaMKII)
inhibitor CK59 inhibited multiple voltage-gated calcium channels, including
the L-type channel during depolarization in a dose-dependent manner. The
use of another CaMKII inhibitor, cell permeable autocamtide 2-related
inhibitory peptide II (Ant-AIP-II), failed to similarly decrease calcium current
or entry in hippocampal cultures, as shown by ratiometric calcium imaging
and whole cell patch clamp electrophysiology. Notably, inhibition due to CK59
was reversible; washout of the drug brought calcium levels back to control
values upon depolarization. Furthermore, the IC 50 for CK59 was
approximately 50 μM, which is only five fold larger than the reported IC 50
values for CaMKII inhibition. Similar nonspecific actions of other CaMKII
inhibitors KN92 and KN62 have previously been reported. In the case of all
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three kinase inhibitors, the IC50 for calcium current inhibition falls near that of
CaMKII inhibition. Our findings demonstrate that CK59 attenuates activity of
voltage-gated calcium channels, and thus provide more evidence for caution
when relying on pharmacological inhibition to examine kinase-dependent
phenomena.
Keywords: Calcium-calmodulin dependent kinase II, CaMKII, calcium
channel, kinase inhibitor, nonspecific inhibition.

Introduction
`Calcium-calmodulin dependent kinase II (CaMKII) is a crucial
signaling molecule involved in many of the most fundamental
behaviors of neurons, such as gene expression and synaptic plasticity
due to long term potentiation. It follows that the distribution of this
protein is widespread throughout the nervous system, and makes up
between 1 – 2% of total protein content in neurons. Given both its
importance and its abundance, CaMKII mediated processes are
currently under intense investigation. One of the most common ways
to study the activity of CaMKII is to inhibit it with pharmacological
agents, then investigate changes in the neuron when CaMKII is no
longer active. Unfortunately, a common problem with kinase inhibitors,
including CaMKII inhibitors, is their lack of specificity. Therefore, new,
more specific inhibitors are always in demand. This demand extends to
a clinical setting, where more specific CaMKII inhibitors may help avoid
potentially harmful side effects.
Over 30 different isoforms (made up of various alternatively
spliced α, β, δ, and γ subunits) of CaMKII have been reported (for
review, see Fink and Meyer, 2002; Wayman et al., 2011). The primary
neuronal subunits are α and β, which are highly homologous. Subunits
come together either as homo- or heterododecihedromers, with each
subunit containing a catalytic, regulatory, and oligomerization domain.
The structure of CaMKII is often described as a petal, where the
oligomerization domain makes up the inner core, while the catalytic
and regulatory domains form a stack of 2 hexomers (Gaertner et al.,
2004; Rosenberg et al., 2006). When calmodulin (CaM) binds to the
regulatory domain, autoinhibition is disrupted, and the particular
subunit interacting with CaM is free to autophosphorylate neighboring
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subunits, which causes their catalytic subunits to become active.
Kinase inhibitors reduce the activity of the enzyme in different ways.
For example, one of the most commonly used inhibitors, KN93 works
to compete with CaM binding to the regulatory domain. This is in
contrast to an inhibitor such as autocamtide 2-related inhibitory
peptide (AIP); unlike KN agents, AIP also inhibits the catalytic function
of activated CaMKII (Ishida et al., 1995; Song et al., 2010). Thus, with
many different forms of inhibition may come many different off target
effects.
CaMKII phosphorylates a wide variety of proteins to modulate
their activity, including voltage gated calcium channels. Calcium
channels are implicated in a diverse array of physiological processes,
such as muscle contraction, neurotransmitter release, and gene
expression. In neurons, there are 3 classes of voltage gated calcium
channels, based on their pore-forming α1 subunit (Cav 1.x, Cav 2.x,
and Cav 3.x, for review see Catterall, 2011). They can further be
divided into various isoforms based on their pharmacological and
kinetic profiles. For example, Cav 1.2 and Cav 1.3 are sensitive to
dihydropyridines, activate at high voltages, and are known as L-type
channels for their long lasting current. Cav 2.1 and Cav 2.2 are known
as N- and P/Q-type channels, are sensitive to certain cone snail toxins,
and mediate synaptic release. Cav 2.3 was given the name R-type
channel due to its resistance to most channel toxins, with a partial
exception being the scorpion toxin SNX-482. Calcium channels are
extensively regulated, either positively or negatively. Regulation
occurs at various sites on the N- and C-terminals, or within the
intracellular loops of the channel. G protein βγ subunits (Li et al.,
2004) as well as multiple protein kinases (Mitterdorfer et al., 1996;
Park et al., 2006; Wang et al., 2009, Bray and Mynlieff, 2011) have
been shown to interact with all types of voltage gated calcium
channels. Since levels of intracellular calcium often work as a switch
for many physiological processes, there is a great deal of interest
surrounding how the behavior of these channels can be modified by
various signaling molecules.
Kinase inhibitor studies have been complicated by nonspecificity
and off target effects of compounds used to inhibit CaMKII. An
example of this nonspecificity is the interaction of the CaMKII inhibitor
KN93 with calcium channels (Gao et al., 2006). Previously regarded as
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one of the cleanest, most potent CaMKII inhibitors in existence, KN93
was shown to reversibly inhibit only L-type calcium channels. Thus,
studies investigating processes or pathways involving both CaMKII and
L-type channels will be confounding without the use of other, more
specific inhibitors. Recently Konstantopoulos et al. have developed a
compound known as CK59 which has been shown to inhibit CaMKII
activity (Konstantopoulos et al., 2007). While originally created to
investigate the kinase responsible for insulin mediated GLUT 4 glucose
transporter translocation, CK59 also offered an attractive option to
those studying CaMKII and calcium channels, due to its potency (IC50
<10 μM) and cell permeability. However, data here suggest that
similarly to KN93, CK59 also inhibits calcium channels in a reversible
manner, despite being structurally distinct. Furthermore, while L-type
channels appear to be dramatically inhibited, it appears to inhibit other
voltage-gated calcium channels as well.

Methods
Hippocampal cell culture
All animal protocols were approved by the Marquette University
Institutional Animal Care and Use Committee and followed the
guidelines set forth by the U.S. Public Health Service. Briefly, neurons
from the superior region of the neonatal rat hippocampus were
cultured as previously described (Mynlieff, 1997). Neurons were
dissociated from 6–8 day old Sprague-Dawley rat pups, plated on
poly-L-lysine coated dishes (1 mg/mL, MW 38,500–60,000; SigmaAldrich, St. Louis MO) and kept in culture for 20–24 hours to allow
recovery from enzymatic digestion before experimentation. Cultures
were maintained in Neurobasal A media supplemented with B27 (Life
Technologies, Carlsbad CA), 0.02 mg/mL gentamicin (Life
Technologies), and 0.5 mM L-glutamine (Sigma-Aldrich).

Calcium Imaging
Cultured neurons were incubated in 5 μM Fura-2 acetoxymethyl
ester (Fura-2 AM, Life Technologies, Carlsbad CA) in calcium imaging
Ringer’s solution (CIR, 154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 10 mM HEPES, 11 mM glucose, pH 7.4 with NaOH) for 1 hour at
room temperature in the dark. Cells were rinsed and incubated for 30
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minutes at room temperature in CIR without Fura-2 AM to allow for
de-esterification. Depolarization was induced by application of high
potassium solution (100 mM NaCl, 50 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 10 mM HEPES, 11 mM glucose, pH to 7.4 with NaOH) for 30
secoonds to open voltage-gated calcium channels. Inhibitors were
perfused onto the cells in CIR for 15 seconds, followed by high KCl
solution with inhibitor for 35 seconds. Neurons were excited at 340 nm
and 380 nm, and emissions were measured at 510 nm using Slidebook
5.0 software (Intelligent Imaging Innovations, Denver CO). The ratio
of the emissions intensity when Fura-2 is excited at 340 nm and 380
nm is directly correlated to changes in intracellular calcium
(Grynkiewicz et al., 1985). Average data represent the mean ± SEM.

Electrophysiology
Whole cell electrophysiological recordings were performed as
described previously (Carter and Mynlieff, 2004; Bray and Mynlieff,
2009; Bray and Mynlieff, 2011). Data were acquired using a Dagan
3900A patch clamp amplifier (Dagan Corporation, Minneapolis MN),
Digidata 1322A acquisition setup, and pClamp 10.0 software
(Molecular Devices, Sunnyvale CA). The extracellular solution
contained 10 mM CaCl2, 145 mM tetraethylammonium chloride, 10 mM
HEPES, and 1 μM tetrodotoxin (Sigma-Aldrich, St. Louis MO), pH 7.4.
Recording electrodes with resistances of 3–8 MΩ were pulled from
borosilicate glass on a Flaming/Brown Micropipette Puller (model P87,
Sutter Instrument Co., Novato CA) and filled with 140 mM Csaspartate, 5 mM MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATPNa2, and 0.1 mM GTP, pH 7.4. Cells were held at −80 mV and
depolarized with a 300 ms pulse to +10 mV. Whole cell currents were
electronically filtered at 1 kHz and digitized at 2 kHz. Linear
components of leak current were subtracted posthoc by the passive
resistance protocol in pClamp 10.0. CaMKII inhibitors were applied to
the cells using a U-tube delivery system, constructed with PE-10
polyethylene tubing housed in a glass tube, which allowed for rapid
application and removal of the compound that was gravity fed onto the
cell and removed via suction. Averaged data represent the mean ±
SEM.

Cellular and Molecular Neurobiology, Vol. 33, No. 5 (July 2013): pg. 723-729. DOI. This article is © Springer and
permission has been granted for this version to appear in e-Publications@Marquette. Springer does not grant permission
for this article to be further copied/distributed or hosted elsewhere without the express permission from Springer.

5

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Chemicals and reagents
The cell permeable CaMKII inhibitor 2-(2-Hydroxyethylamino)6-aminohexylcarbamic acid tert-butyl ester-9-isopropylpurine (CK59,
EMD Millipore, IC50 < 10 μM) was dissolved in DMSO and diluted
1:200,000-1:250 to produce final concentrations between 500 nM and
250 μM. A second CaMKII inhibitor, cell permeable autocamtide-2
related inhibitory peptide II (Ant-AIP-II, EMD Millipore catalog
#189485), was dissolved in distilled water and diluted 1:1000 to
produce a final concentration of 50 nM. This compound is an
autocamtide-2 related inhibitory peptide (AIP) analog that contains the
Antennapedia transport peptide sequence fused to the amino terminus
of autocamtide-2 related inhibitory peptide II (AIP-II, EMD Millipore
catalog #189484, IC50 = 4 nM) to enhance cell permeability. Ant-AIPII has been demonstrated to successfully enter both glia and neurons
in culture (Watterson et al., 2001; Mauceri et al., 2004). In
electrophysiological experiments designed to block N and P/Q channel
activity, 2 μM ω-conotoxin MVIIC (Sigma-Aldrich, St. Louis MO) was
added to the bath and U-tube. In experiments where L-channel activity
was blocked, 20 μM nimodipine (Tocris Bioscience, Minneapolis MN)
was added to the bath and U-tube in electrophysiological experiments,
or perfused onto the cells in calcium imaging experiments.

Results
CK59 inhibits depolarization induced calcium entry
The effects of CaMKII inhibitors CK59 and Ant-AIP-II were first
explored with the use of ratiometric calcium imaging. Cells were
depolarized with a high KCl solution in the presence and absence of
various CaMKII inhibitors. Cells were treated with CK59 for 15 seconds
prior to the depolarization with high KCl. There was no change in the
fluorescence ratio during this pretreatment suggesting that CK59 does
not affect the baseline extrusion levels of calcium. It is clear that in the
presence of CK59 (50 μM) the high KCl solution was not able to elicit
as large an increase in intracellular calcium (Fig. 1A). This effect was
reversible, as the response to a KCl-induced depolarization after
washout of CK59 was restored to the pre-CK59 level. In contrast, the
increase in intracellular calcium with the high KCl solution was not
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affected by the inclusion of the second CaMKII inhibitor, Ant-AIP-II (50
nM, Fig. 1B). On average, the increase in intracellular calcium with
high KCl stimulation was reduced to 44.83 ± 1.88% of control with
CK59 (N = 128; paired t-test, p<0.001) and only reduced to 94.68 ±
1.29% of control with Ant-AIP-II (N = 255, Fig. 1C). This result
together with the lack of effect on baseline extrusion suggests that the
novel CaMKII inhibitor CK59 shows off target inhibition of voltage
gated calcium channels. However, the data do not exclude the
possibility that there may be effects on extrusion in the presence of
high intracellular calcium.
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Fig. 1

CaMKII inhibitor CK59 but not Ant-AIP-II significantly attenuates the amount

of high KCl induced increase in intracellular calcium when measured with Fura-2
ratiometric imaging. A) Example of 340/380 ratio obtained with high KCl solution alone
or high KCl solution in the presence of 50 μM CK59. Each line shown represents an
individual cell (N=6). B) The same conditions as in A, but using 50 nM Ant-AIP-II
(N=6). C) Average change in intracellular calcium as determined by the 340/380 ratios
with KCl alone (solid bars), KCl with CK59 (crossed hash bar, N = 128), or KCl with
Ant-AIP-II (diagonal hashed bar, N = 255). *Paired t-test, p < 0.001).

High KCl-induced increases in intracellular calcium were
measured in the presence of 500 nM – 250 μM CK59 (Fig. 2). The
solubility of CK59 in DMSO limited the highest concentration used to
250 μM. Control experiments with DMSO, diluted 1:250 in CIR with no
CK59, verified that DMSO alone did not affect high KCl-induced
calcium influx at this concentration (data not shown). The doseresponse curve data was fit with a 3 parameter sigmoidal curve that
assumed if the concentration was increased to high enough levels, all
calcium entry would be blocked. The curve generated an IC50 of 52 μM.
It is possible this is an overestimate; if all calcium entry is not
completely inhibited and instead 70% CK59 mediated inhibition is the
actual maximum, then the IC50 would be closer to 22 μM. CK59’s IC50
for inhibition of CaMKII activity is < 10 μM. Other nonspecific CaMKII
inhibitors that inhibit L-type calcium channels are more potent, both in
their primary and off target effects. For example, the IC50 for KN93’s
effect on CaMKII is 0.37 μM (Sumi et al., 1991), whereas its IC50 for Ltype channel inhibition is approximately 1 μM (Gao et al., 2006). The
IC50 of a related inhibitor, KN62, is 0.9 μM for CaMKII activity; the IC50
for its off target effects on calcium entry is approximately 0.5 μM
(Sihra and Pearson, 1995). Given the relatively close IC50 values for
primary and off target effects of these CaMKII inhibitors, one must be
extremely cautious when selecting a compound to inhibit CaMKII
activity.
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Fig. 2

Various doses (0.5, 5, 20, 50, and 250 μM; n = 122, 51, 166, 326, and 122,

respectively) of CK59 were applied to cells during high KCl-induced depolarization. The
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percent inhibition of high KCl induced intracellular calcium by CK59 was calculated as
100%−(100×(Fura Ratio in CK59+KCl)/(Fura Ratio in KCl)). Data were fit with a 3
parameter sigmoidal curve (r2 = 0.983). This allowed calculation of the IC50 value for
CK59, 52 μM.

The effects of CK59 on voltage gated calcium currents was
measured directly using whole cell patch clamp recording. Figure 3
illustrates the calcium current elicited in the presence and absence of
CK59 (50 μM). The total current was reduced with CK59 in a reversible
manner (Fig. 3A). Calcium currents often change during recording so
that the data were adjusted for run-up or run-down prior to measuring
the magnitude of current inhibited (Carter and Mynlieff, 2004; Bray
and Mynlieff, 2009; Bray and Mynlieff, 2011). Typically a few control
currents were measured both before and after CK59 application. These
currents were fit with a linear regression and the current in the
presence of CK59 was compared back to the linear regression line
(“expected current in the absence of inhibitor”; Fig. 3B). A change in
the current magnitude was only considered significant if it fell outside
of the 95% confidence interval for the linear regression (dashed line in
Fig. 3B). In all 15 cells tested, CK59 significantly reduced the current
with an average reduction of 32.05 ± 1.86% when compared to the
linear regression line (Fig. 3E). The difference in reduction of calcium
entry observed when using ratiometric calcium imaging versus whole
cell patch clamp electrophysiology likely stems from the length of time
neurons are stimulated. In calcium imaging experiments, neurons
were depolarized for 30 seconds so that the majority of calcium influx
is through long lasting L-type channels, whereas electrophysiological
experiments depolarize neurons for a relatively short 300 ms. The
currents measured in response to a short depolarization to +10 mV
are likely comprised of L-, N-, P/Q-, and R-type currents. As seen with
ratiometric calcium imaging, electrophysiological recordings illustrate
the nonspecificity of CaMKII inhibitor CK59, as it decreases voltage
gated calcium current.
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Fig. 3

Calcium currents elicited by a 300 ms depolarizing pulse to +10 mV from a

holding potential of −80 mV demonstrates the nonspecific effects of CK59 on calcium
channel types. A) CK59 application reduces current in normal recording solution.
Voltage gated calcium currents were recorded before (black trace), during (gray trace)
and after (light gray trace) application of CK59. B) Control calcium currents were
measured before and after CK59 application (filled circles) and fit with a linear
regression line and 95% confidence interval (dashed line). Calcium currents elicited in
the presence of CK59 (gray diamonds) fell outside of the confidence interval for the
control currents. The percent of current blocked by CK59 was calculated by comparing
the current in the presence of CK59 to the regression line for that specific time point.
C) 20 μM nimodipine was bath applied and voltage gated calcium currents were
recorded before (black trace), during (gray trace) and after (light gray trace)
application of CK59 (50 μM). D) 2 μM ω-conotoxin MVIIC was bath applied and voltage
gated calcium currents were recorded before (black trace), during (gray trace) and
after (light gray trace) application of CK59 (50 μM). The traces illustrated in A, C, and
D were recorded in different neurons. E) Average decrease in voltage gated calcium
current seen with CK59 application (50 μM) in control bathing solution (N=15), with
20 μM nimodipine (N=7), and with 2 μM ω-conotoxin MVIIC (N=5) in the bath.
*Unpaired t-test, p < 0.001.
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CK59 decreases calcium entry through more than one
voltage gated calcium channel
Since it had previously been reported that the CaMKII inhibitor
KN93 reduced L-type calcium current, we sought to assess whether Ltype calcium channels were similarly inhibited by CK59 with whole cell
recording. Calcium currents were measured during the final 50 ms of a
300 ms depolarizing pulse to +10 mV to minimize the contribution of
fast (T-type) current while maximizing the long lasting (L-type)
component of the current. Notably, N-, P/Q-, and R-type currents are
still present during this period, as demonstrated in figure 3C, where
current still remains after the L-type calcium channel antagonist
nimodipine (20 μM) was used. Thus, the current remaining in the
presence of nimodipine should primarily be comprised of N-, P/Q-, and
R-types of calcium current. If CK59 only inhibited L-type channels,
then the addition of CK59 in the presence of nimodipine should not
further inhibit the total calcium current because the channels would
already be blocked. Figure 3C illustrates the calcium current elicited in
the presence and absence of CK59 (50 μM) in a cell pretreated with
nimodipine (20μM). The current was reduced with CK59 in a reversible
manner similarly to the non-nimodipine treated cells. CK59 caused a
significant decrease in calcium current with an average reduction of
27.54 ± 4.66% (N = 7, Fig. 3E). The reduction in voltage gated
calcium current elicited in the presence of the L-type calcium channel
antagonist implicates that CK59 may inhibit N-, P/Q-, and/or R-type
current(s).
Ratiometric calcium imaging experiments were done to confirm
that CK59 can reduce calcium entry in the presence of an L-type
calcium channel antagonist. Nimodipine (20 μM) was present in the
bath for the entire time course of the experiment to block L-type
calcium channels, and high KCl solution alone or high KCl solution with
CK59 (50 μM) were applied acutely (Fig. 4). Application of CK59 under
these conditions reduced high KCl induced calcium entry to 43.73 ±
1.38% (N = 185) of the average calcium entry elicited by high KCl
application alone. Given that both calcium current and entry decreased
in the presence of the L-type calcium channel blocker nimodipine, it
was hypothesized that CK59 exerts its effects by inhibiting another
calcium channel type than L-type calcium channels, suggesting a
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different nonspecific effect from that of CaMKII inhibitor KN93 (Gao et
al., 2006). However, the effect of CK59 on L-type calcium channels
may have been masked because nimodipine would already be blocking
L-type channels in these experiments. Therefore, experiments were
performed to address the effect of CK59 more specifically on L-type
channels.

Fig. 4

aMKII inhibitor CK59 attenuates the amount of high KCl induced increase in

intracellular calcium in the presence of the L-type channel blocker, nimodipine when
measured with Fura-2 ratiometric imaging. Nimodipine (20 μM) was perfused during
the entire measurement period. The 340/380 ratio was measured in response to high
KCl solution before and during CK59 (50 μM) application and representative cells are
shown (N = 7). Each line represents an individual cell.

To clarify if L-type calcium channels could also be blocked by
CK59, ω-conotoxin MVIIC (2 μM) was added to the bath during
electrophysiological studies to block N- and P/Q-type calcium channels.
The current in figure 3D is reduced due to the presence of MVIIC. On
average, cells treated with MVIIC displayed 74.25% less calcium
current than control cells (data not shown). Comparing the raw current
in 3C with the L-type channel blocker nimodipine with the raw current
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in 3D with ω-conotoxin MVIIC suggests that while L-type current is
certainly present in these neurons, currents sensitive to ω-conotoxin
MVIIC (N- and P/Q-type) make up the bulk of the high voltage
activated whole-cell current in neonatal neurons of the superior
hippocampus when a 300 ms depolarizing pulse is applied. Addition of
CK59 (50 μM) reduced the current even further, so that very little
current remained when MVIIC and CK59 were simultaneously applied
(Fig. 3D). Calcium currents in these studies were decreased an
average of 67.47 ± 10.38% (N = 5; Fig. 3E), which was a significantly
larger decrease by CK59 than that seen when ω-conotoxin MVIIC was
not present (unpaired t-test, p < 0.001, Fig. 3E). Furthermore, total
calcium current measured in 4 of 5 cells was nearly completely
abolished with measurements below 10 pA. These data suggest that
CaMKII nonspecifically inhibits N-, P/Q-, L-, or R-type current, or some
combination of these currents collectively.

Discussion
Data presented here clearly show the off target action of novel
CaMKII inhibitor CK59 on voltage gated calcium channels. Both
electrically stimulated currents in whole cell recording and high KClinduced calcium influx were significantly reduced by CK59 in a dosedependent manner. However, determining the exact channel(s)
targeted by CK59 is more difficult. Studies done in the presence of ωconotoxin MVIIC strongly argue for L-type channel inhibition due to the
drastic reduction in expected current as well as the nearly complete
extinction of L-type current in the majority of cells tested when CK59
was applied. However, in the presence of nimodipine, both calcium
current and calcium entry decrease upon application of CK59. This
may seem to suggest that L-type channels are not affected; however
when nimodipine is present, L-type current is already being blocked.
Therefore, any effect of CK59 on L-type channels would be masked.
The decrease in calcium levels in the presence of nimodipine after
CK59 application does suggest inhibition of additional channels besides
only the L-type channel. One possibility is that R-type calcium
channels are inhibited by CK59. In a report by Castelli and Magistretti
(Castelli and Magistretti, 2006), R-type current in the entorhinal cortex
made up only 11–13% of total calcium current. The small amount of
current seen in the cells treated with ω-conotoxin MVIIC also suggests
a large component of calcium influx is through N- and P/Q-type
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channels. Even if complete blockade of R-type current was assumed,
this would likely not make up for the amount of inhibition seen in
nimodipine-treated cells. There was 27.54% reduction in whole cell
calcium current and 56.27% reduction in high KCl mediated increase in
intracellular calcium when nimodipine was present, suggesting that
even if R-type channels are affected along with L-type calcium
channels, there must be another channel that is inhibited by CK59. A
second possibility is that L-type channels were not completely blocked.
This seems unlikely due to the high concentration of nimodipine used
in these studies (IC50 = 139 nM for CaV 1.2 and 3 μM for CaV 1.3;
Catterall et al., 2005). It is more likely that at least one of the
channels blocked by ω-conotoxin MVIIC is susceptible to inhibition by
CK59. In either case, it seems that CK59 inhibits L-type channels as
well as others. While the identity of the other channels CK59 may
inhibit in addition to L-type channels is not completely clear, it is
evident CK59 has off target effects that inhibit the entry of calcium
into neurons.
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